An Oral History Of Blade Runner’s 2019 Los Angeles, Because The Future Has Arrived – laist.com

The Blade Runner future that we haven't quite reached. (Courtesy Warner Bros.)From Blade Runner's opening titles. (Courtesy Warner Bros.)

Los Angeles November, 2019.

Early in the 21st century, LAist has put together an L.A.-centric oral history of the 1982 seminal science fiction film Blade Runner.

Thirty-seven years after it came out, we are now in the month that the movie took place. At the end of the month, Blade Runner's Los Angeles of the future will officially take place in the past. Hold on tight for this trip through time and space.

We've spent months speaking with some of the minds that helped bring you the film.

Below is an account of how they created Blade Runner's fictional November 2019 and what they think about how the real one turned out.

SETTING BLADE RUNNER IN LOS ANGELES

As the movie was developed, the plan wasn't always for it to be set in L.A.

Screenwriter Hampton Fancher: There were a lot of elsewheres. There were some great places to overlay our deal on, citywise Hong Kong, Mexico City. In the beginning, we were talking about about London.

Visual Futurist Syd Mead: Originally, the theoretical city in which Blade Runner was taking place was called "San Angeles," on the imagination that it would be constant city from San Francisco all the way down to the border to Mexico.

Los Angeles was just convenient for cost purposes for shooting you didn't have to move out of the city.

Production Executive Katy Haber: I went with [Blade Runner director] Ridley [Scott] looking for locations in Chicago and New York, because he was looking for the most appropriate city where he could find the best locations, and we couldn't find any locations that represented his vision of what Blade Runner would be. And so we decided to stick to Los Angeles, and shoot the whole film on the Warner Brothers lot.

Fancher: But in the writing, before that, Ridley's got a rich imagination, and I'm crazy so I kept writing for different climates and different circumstances, mechanically and weatherwise. So it did change around a lot, before it finally got simple, into L.A.

Art Director David L. Snyder: The whole idea was, OK, we would shoot in L.A. wherever we could the Bradbury Building, Union Station.

HOW RAY BRADBURY GAVE US BLADE RUNNER

One of Hampton Fancher's friends gave him money to option an existing property, with the hope of Fancher legitimizing himself in Hollywood.

Fancher: It shows how out of it I was in trying to be in it, acknowledging that I was out of it to myself, and then thinking, "OK, how do I stop being out of it? Well, I get some legitimate illogical narrative ideas" some novel, you know?

So I decided on three writers that I might be able to option their material and get some producer, or myself as producer, and then get some writer to do a screenplay on it, and maybe make a movie.

And so the three projects were Do Androids Dream of Electric Sheep, Naked Lunch, and a collection of Bukowski. Which, in 1975, forget it I mean, that was nuts. Hollywood would not touch any of that, but I was looking for something "commercial," and I thought that all of these things were coming.

There would be no Blade Runner if there was no Ray Bradbury. I couldn't find Philip K. Dick. His agent didn't even know where he was. And so I gave up.

And then I was walking down the street and I ran into Bradbury he directed a play that I was going to do as an actor, so we know each other, but he yelled "hi" and I'd forgot who he was.

So at [my girlfriend Barbara Hershey's] urging I was with her at that moment she said, "Talk to him! That guy really wants to talk to you," and I said "No, f- him," and keep walking.

But then I did, and then I realized who it was, and I thought, "Wait, he's in that realm, maybe he knows Philip K. Dick." I said, "You know a guy named" "Yeah, sure you want his phone number?"

My friend paid my rent for a year while I wrote, because it turned out we couldn't get a writer. My friends kept on me about, well [if you can't get a writer,] then you write.

So then, as soon as I started, I got totally involved. I was really immersed, and I worked hard at it, and the rest is Blade Runner. It was mercenary. But when I started writing it, then I became sincere, and it became significant to me.

DESIGNING NOVEMBER 2019's LOS ANGELES

Syd Mead hadn't worked in Hollywood before, so when Ridley Scott wanted to bring him on board to design the future, Haber came up with the idea of crediting him as a "visual futurist."

Snyder: Ridley was the executive production designer, due to the fact that he had been a BBC art director and had art directed and directed in films, shot camerawork, many commercials.

Syd Mead was the futurist. If I were doing a film on, say, the second World War, I'd go back to the archives and do the research, and there's plenty of it stills, magazines, print, film archives.

And in this case, because the film took place 40 years in the future, we depended on Syd, who was an industrial designer he's not an art director, or a production designer, he's a real-life designer.

We all decided, let's do something great.

Mead: [My primary influence was] from Chicago and New York, because they're grid cities. And New York already had buildings over 1,000 feet well, the Empire State Building. And so I thought, well let's add another thousand feet or so why not?

So I had this vision of these incredible tall buildings, and that triggered the idea of how do you get in and out of a building that's 3,000 feet tall? Well, you need access on the ground plane. And that's why they had these pyramids at the bottom, for greater access around the perimeter to get into the building in the first place.

Snyder: What Ridley said was, he would draw, and Syd Mead would draw, and everyone would draw, and then "the poor bastard art departments" had to build everything.

On the first day of shooting, Ridley would look through the lens, and everything would change. My job became the reconstructor art director, turning everything upside-down and sideways, to better effect because Ridley's brilliant.

AN ENVIRONMENTAL MESSAGE BASED IN ITS TIME

Fancher: The reason I was able to write the movie, and not be distracted as I always am by a million other things, is because I was very serious about the demise of the planet. You know, this is '75. This is acid [rain]. Until 1980, it was like, Whole Earth Catalog, CoEvolution. It was important to me.

Snyder: It was an idea that the environment is crumbling, and the idea was that the rain in the film was like acid rain. That's why people were moving off-world to get off this planet before it disintegrated.

I think we were making a statement about the government, and the future, and the climate, and the disparaging rift between rich and poor.

Fancher: I mean, I was devastated that animals were disappearing at the rate they were disappearing the rainforest was going bye-bye. It was like, "this is f-ed up," and I was angry and sad.

And so that idea kept me rolling, because I had something to write for. I got the cue from the book, but I was in that mindset anyway.

Fancher was replaced on the film by writer David Peoples, who executed Ridley Scott's vision for what needed to happen with the screenplay.

Fancher: I was devastated. I hated it. I didn't understand that it might be a good idea. If David Peoples hadn't have come, there would be no Blade Runner that's for sure.

Because where I was going was not right I mean, it would have been a different movie. If he hadn't have come, if I would've stayed, Blade Runner would have been one of those little movies Soylent Green, or something that maybe you could rent once in a while or something, but we wouldn't know about it.

FINDING A NEW WAY TO SHOOT THE BRADBURY BUILDING

Fancher: [Ridley] was location hunting when I was writing, and I remember him coming back from a scout, telling me that he'd seen a building that he liked. And I remember screaming, "What?! You can't use the Bradbury Building!"

And he said, "Why Not?" I said, "Because you're a Brit you don't understand, that's been in every f-ing TV show, every other day, for 50 years."

He was walking out the door, and I said, "I'm telling you, you're making a big f-ing mistake." And he said, "No, I'm not." And I said something about the way that it had been done it had been done in every detective show, and every hot show it's been seen.

And then he laughed, and he looked at me "Not the way I'll do it." And I thought, "You arrogant idiot."

Snyder: That was a working building at the time, and when I built the marquee outside, the canopy, we couldn't touch their building at all. So what we had to do, old-school, was take a calipers and measure the building, and then cut everything to it, and then gently push the building into place without even touching their building.

So if you look close at those scenes, with Pris Darryl Hannah if you look close, you can see that there's a tiny little space between my set, and the Bradbury Building.

Haber: We shot the entire end of the film, and J.F.'s apartment, in the Bradbury Building. But the Bradbury Building is a fully functioning and existing office block.

Snyder: The interior, we started shooting at 6 o'clock at night, and we had to be out by 6 o'clock in the morning, and we had rain inside the building.

What we did was, we got barrels of crumbled cork, which looks like dirt. So we spread the cork all over the floors, as opposed to dirt, because it looks like dirt. And in the morning, we would just sweep up the cork, which had absorbed the majority of the water, and mop the floors down, and we had to do it every night.

It was really treacherous and difficult. And with Ridley, there was no "I can't do it, I don't know how" it just had to be done.

Fancher: Boy, was [Ridley] right. There's reasons for his confidence. He f-ing nailed it.

CREATING A FAKE DOWNTOWN L.A. BUILDING

The movie features a climactic chase, with Rutger Hauer's Roy Batty hunting down Harrison Ford's Rick Deckard.

Snyder: So we went to a building downtown it's called the Rosslyn Hotel, the Million Dollar Hotel. Many films have been shot there, music videos, and it has a heart-shaped neon sign on the rooftop.

He has to jump from one rooftop to the other. Well, of course, it's quite dangerous. I consulted an engineer, and he said the building was built in 1912. It was derelict when I was there I mean, it was really in bad shape.

So he said that we would have to build another platform on top of the rooftop to take the weight of all the equipment and the crew, and it was going to be maybe 50,000, 100,000 dollars.

I said to Ridley, look, you know what: I can build a building on the backlot that's 20 feet high, 20 feet wide, and 20 feet deep, and I'll put it on wheels, and we'll be able to move it around. Which we did, frequently.

So it's a landmark building it's the one landmark building that I reproduced, meticulously. I mean, it's a dead match to the building. And that cornice on the roof is made of steel well mine is made of fiberglass, but who knows, except me.

And Harrison Ford was able to climb up to the rooftop because I had him get on a lift, and he would put his hands where he would reach, and I would mark the chalk, and we'd cut out a hole and put rubber tubing so he could grab it. So when he's ascending the rooftop there, he looks like he's pretty good at it, but I gave him a little help.

[Ridley] would say "Do this," and I would do that, and he would say "OK, I want something moving in the frame" at 3 o'clock in the morning, and I would come up with things like the landmark piece in the film.

All those fans turning and strobe-lights they weren't there the day we got there. They were made up of paper plates and cardboard, and put on C-stands, and there were no motors, and so the prop guys would have to spin the fans and then run out of the shot. [laughing]

It was a DIY situation for me, where he would say "Make something happen," and I would say "What do you want me to make happen?" And he said, "Well you're the art director, you figure it out."

WHY BLADE RUNNER'S WRITER GOT REPLACED

Fancher: [Ridley Scott and I] definitely had disagreements. And it was my fault. I was naive and stupid. I didn't know I thought that the project was mine, you know?

He was extremely inspiring. But I also had trouble. By the way, the things I disagreed with it turns out he was right and I was wrong, for sure. I was naive about heroes.

Haber: I spent many weeks at the Chateau Marmont with David [Peoples] rewriting Hampton Fancher's original screenplay.

The problem was that Hampton was around when David was at the Chateau Marmont, and at first he didn't know it was happening.

Fancher: [Ridley's] good. He knows the business of making a movie, and what has to happen, and I never have. I'm not realistic that way. And he's very realistic.

So we had two falling outs. I left the picture, but I came back at the end, and we continue to know each other. I adore him.

For a while, I didn't want anything to do with the picture I tried to get my name off it. So that's how stupid I am.

WHAT CHANGED FROM THE ORIGINAL BLADE RUNNER SCRIPTS

Fancher: I didn't like that Rachel, I thought, was weakened. I wanted her to be more powerful than everybody mentally, emotionally. [In mocking voice] "Oh, god, what am I going to do?" I didn't want that, and I fought that and I was wrong.

And I wanted Deckard to be even more vulnerable, and I was wrong there too. When Batty's going to drop him off the roof, Ridley wanted me to have Deckard be defiant. I said, "He'll suck his d-! He'll do anything he's not defiant!"

The chess game I thought that was ridiculous. He gets into the Tyrell Corporation playing chess? The most surveilled place on the planet? He goes up an elevator with Roy Batty the most sought after renegade in the world? Noooo. I had another way to do it.

Then I think, they're whispering behind my back, "Well, Hampton doesn't seem to understand movies, Saturday matinees, whatever." You can get away with things, the audience will love it whatever that is. And I was being, in some stupid artistic way, conservative. So there were a lot of things I resisted in fact, I didn't cooperate.

SHOOTING ON THE WARNER BROS. BACKLOT

Mead: Once we got going, the whole Warner Brothers backlot became Blade Runner Land.

Snyder: That was when the decision was made that we only shot at nighttime. Because at nighttime, like in Tokyo or whatever the distance from the camera across the backlot, you don't know what's beyond that it could be Hong Kong.

Mead: I knew Ridley wanted to have a very dense, packed set look to the whole thing. So once I got pictures of the backlot, I started to overlay them with a lot of stuff wiring, and tubing, and so forth.

The idea of the city as a machine took on a whole new idea we called the look "trash chic," or "retro deco." I mashed together every single architectural style I could think of, indiscriminately, just to make it look packed up and eclectic.

Snyder: This is the first film that Ridley did in Hollywood, L.A. So he had this idea, the most brilliant idea of all: we would go night-scouting in downtown L.A., which was really treacherous, really tough.

And so, Ridley said, "Look there's 1920 on this building, and then they put a layer of 1940 on the building, and then they put a layer of 1960 on the building," and it was a stratification thing.

So when it was decided that we were going to shoot on the Warner Brothers backlot the buildings that were built on the backlot started in 1924. And then went through all those periods, from 1924 to 1980.

When we were in pre-production, Ridley took us into the screening room and we ran the film Logan's Run. And at the end of the film, he said, "Do you see that? We don't want to do any of that, at all. This is exactly what we don't want to do the Earth is leveled, and you start over again."

Mead: The first thing Ridley said out of his mouth was, "This is not going to be Logan's Run." I thought, "Well, that gives me a clue."

Snyder: We started with 1920, and 1940 the backlot, various structures over time and then we added 2019 to it. The layers, and layers, and layers of stuff is what really makes that film look like it does.

Fancher: I didn't understand money at all. I remember a scene, and they told me, "We don't have the money for the street." I said, "What do you mean, money for the street?" "We can't lengthen the f-ing street in the backlot of Warner Brothers to accommodate that." And I said, "Well, just do it it's movies."

THE TERRIBLE, TERRIBLE VOICEOVER AND WHY YOU SHOULD WATCH THE FINAL CUT

Snyder: We all, filmmakers, prefer the Final Cut, because [Ridley] was in charge of the Final Cut. As far as the "director's cut," he wasn't that involved in it.

Haber: We shot the last two weeks in one week, so as not to lose Ridley, god forbid and then the directors strike never happened. So we shot two weeks in one week, and the overtime for the crew meant they shot 24/7, [which cost] 5 million.

That put the movie over-budget, leading to Scott and the other producers being removed from the film, with financiers Bud Yorkin and Jerry Perenchio taking over post-production. Haber was the one member of the producing staff kept on under the new administration.

Haber: When Ridley wanted to do his next two cuts on DVD, he had to get permission from them, because they owned the film.

[When the movie came out,] I felt like I was giving birth in public. And it was really difficult, because it was Bud Yorkin's version of the film, which is why it was not so successful.

The narration, which Bud Yorkin and I dubbed with Harrison Ford, with Harrison doing it very badly in the hope that it wasn't going to be used it was not written by Hampton Fancher or David Peoples. It was written by Bud Yorkin's writer [Roland Kibbee].

And unfortunately, it was used, to Bud Yorkin's and Ridley Scott's demise. Ridley originally called it "Irving the explainer." [Yorkin] used it to tell the story, so Irving the Explainer was the perfect term to describe how irrelevant it was and unnecessary it was, and expecting the audience not to understand the film, so you needed Deckard to explain it.

Read more:

An Oral History Of Blade Runner's 2019 Los Angeles, Because The Future Has Arrived - laist.com

Scientist Rita J. King wears sparkly dress to NASA talk – TODAY

Scientists can be sparkly, and Rita J. King, a scientist who co-directs Science House in Manhattan, is out to prove it.

King is a futurist, which means she analyzes data and makes projections. In her LinkedIn bio, King explains, "I work with teams and organizations to help them take ideas from mind to market, and individual leaders to help them navigate an increasingly chaotic world."

In a tweet earlier this month, King shared photos of herself in a sparkly golden dress, giving a talk at NASA.

Trending stories,celebrity news and all the best of TODAY.

"I came across this gown and remembered the little girls who sent me a letter and asked me to wear something sparkly... so they could believe that scientists could also be sparkly," King wrote in the post.

King's Twitter followers were quick to praise her for showing young girls the best of both worlds.

"My daughter is obsessed with all things sparkly, and she also likes to use tools and tinker," wrote one Twitter user. "I love that she can see women like you!"

"Yes. You have inspired me to take my tiara to work and wear it while Im grant writing!" wrote another.

King made time to respond to her followers' comments, with heart emojis and heartfelt words.

And, in one reply, she said that while she won't always dress in sparkles, she was glad to do it this once.

"I bought it for that talk and thats the only time Ive ever worn it," she wrote.

"I hope you find occasion to wear it again," the follower responded. "It, like you, is born to shine."

Never miss a parenting story with the TODAY Parenting newsletter! Sign up here.

Terri Peters is a writer and editor for TODAY.com and editor of the TODAY Parenting Team. She lives in a small beach town on the Atlantic coast of Florida with her husband and two kids. When she isn't writing, Terri can be found feeding her backyard flock of chickens or exploring Florida's theme parks and beaches with her family.

Read the original:

Scientist Rita J. King wears sparkly dress to NASA talk - TODAY

Scientists Discover New Class of Tiny Black Holes – Futurism

It almost seems like astronomers are in a race to unveil the biggest black holes they can find. Most recently, a team of German astronomers claimed to have discovered a black hole 40 billion times the mass of the Sun.

But what if there are also black holes many magnitudes smaller?

In a study published today in the prestigious journal Science, a team of astronomers from Ohio State University claim to have discovered an entirely new and previously missing class of black holes.

Were showing this hint that there is another population out there that we have yet to really probe in the search for black holes, lead author Todd Thompson said in a statement.

If confirmed, current theories would have to take intoaccount an entirely new class of black hole forcing us to rethink how we understand the way stars and other kinds of celestial objects are born and die.

Thompson and his team were puzzled by the huge gap between the size of the biggest neutron stars extremely dense and relatively small stars that form after larger stars implode after a supernova and the smallest black holes we know of.

Neutron stars are fairly small two to three times the mass of the Sun but stars any larger than that tend to collapse in on themselves and form black holes.

Their smoking gun: a giant red star that was orbiting something that at first appeared to be too small to be a black hole in the Milky Way, but that was much bigger than the neutron stars we know of.

The black hole it was orbiting turned out to be only 3.3 times the mass of the Sun usually the black holes weve found in the past are at least five times the Suns mass or much, much larger.

The discovery could redefine the way we look at the lifecycle of a star.

If we could reveal a new population of black holes, it would tell us more about which stars explode, which dont, which form black holes, which form neutron stars, said Thompson. It opens up a new area of study.

READ MORE: Scientists may have discovered whole new class of black holes [The Ohio State University]

More on black holes: Astronomers Just Spotted One of the Biggest Black Holes Ever

Read more from the original source:

Scientists Discover New Class of Tiny Black Holes - Futurism

Japan Just Unveiled a Supercar Made out of Wood – Futurism

Wooden Car

Japan just unveiled its vision for the car of the future and its made from wood.

Specifically, the cars entire body and much of its structural tub are made of cellulose nanofiber, a super-strong, super-light material derived from plants.

Twenty-two groups contributed to creating the vehicle, which Japans Ministry of the Environment unveiled at the Tokyo Motor Show this week but based on what we know so far, the wooden car is far from road ready.

The wooden car certainly looks futuristic, with its butterfly doors and sharp angles. But its hard to say just how close the vehicle comes to the teams stated goal of a 10 percent weight reduction, and detailsabout whats under the hood are hard to come by.

Carscoops did report that the vehicle is thought to feature a hydrogen fuel cell and have a top speed capped at a mere 12 mph (20 km/h). If thats true, it seems this car is an extremely early concept unless, of course, Japan envisions people driving very, very slowly in the future.

READ MORE: The Car Is Made Of Wood [Jalopnik]

More on wooden cars: New Metallic Wood Could Lead to Super-Light Cars

Originally posted here:

Japan Just Unveiled a Supercar Made out of Wood - Futurism

Iron man: 10 Things Fans Never Knew About The Mark 1 Armor | CBR – CBR – Comic Book Resources

While Captain America has his shield and the god Thor wields hishammer Mjolnir, Iron Man is pretty much defined by his armor. However, Tony Stark's Iron Man suit isn't made from a secret vibranium-based alloy nor is it adivine godlyrelic. The Iron Man suit is a work of cutting-edge technology and like all tech, it must evolve with the times or riskbecoming obsolete.

RELATED: 10 Beatdowns That Tony Stark Never Should Have Survived

As a futurist, Tony Stark hasprobably strip-mined several major veins of ore to build all his Iron Man armors. But before he developedsuch famed suits as the Hulkbuster armor andEXTREMIS, he builthis firstMark I armor with crude tools from salvaged munitions while held captiveby insurgents. Here are ten facts about the Mark I that only a genius like Tony Stark could know:

Click the button below to start this article in quick view

Tony Stark is basically the Steve Jobs of WMDs. As a teenager, he built revolutionary weapons in his dad's garage, reinventing the scienceof micromunitions with his new miniaturized bomblets, then growinghis fortune by developing new military contracts. While abroad to help advise military operations in the field and oversee American troops using his tech, a bomb went off, sending shrapnel jagging into his chest. He was seizedby enemy combatants, taken alive, but slowly dying from his wounds.

Tony's captors wanted himto build them weapons before he died of his wounds. He built the first Iron Man suit instead, using it tofight his way to freedom. Eventually, he'd made other newer armors. But for a very long time, Tony continued to fight wearing his original Mark I Iron Man armor that he built in captivity.

Iron Man is a founding member of the Avengers. Alongside Hulk, Ant-Man, the Wasp, and Thor, the billionaire inventedhelped establish the greatest superhero team in the Marvel Universe. Unlike the other heroes, Tony Stark had no powers. He was just a smart rich unpowered guy ina fancy metal suit.

When he first helped start the Avengers, his armored suit wasn't even all that cutting edge. In fact, when he joined up with the other heroes, he was still wearing the Mark I, the least sophisticatedof all his armors. Still, even thoughit had beenmade with crude tools and leftover parts, it was good enough to make him one of Earth's mightiest heroes.

Just how high- or low-tech the original Mark I is supposed to be depends on who is writing Iron Man at any given moment. Given that the armored Avenger made his debut in Tales of Suspense issue 39 (way back in 1963!) there was not exactly a lot of digital technology around at the time, suggesting his first suit might be an analog armor. Even recent retcons describe his suit as a piece of equipment so unsophisticated he can operate it after taking extreme brain damage.

RELATED: 10 DC Armors More Powerful Than Iron Man's

However, in the original Tales of Suspense story, it's revealed that the Mark I can actually read brain waves! That kind of technology would make the Iron Man armora brilliant invention by even the most modern standards, showing just how geniusTony Stark really is.

As a weapons designer, Tony Stark hasplenty ofblood on his hands. During the "EXTREMIS" storyline which updated his origin story, a reporter informed Tony that 18% of theseedpod bombs which he made for the Air Force had failed to fire at the proper time, resulting in detonations that killed civilian children across the Theater of War.

When Tony Stark invented the Mark I, it saved his life from the shrapnel burying its way toward his heart. It was the first time he ever made something that saved a life. After that, he became a superhero to help others and began using his wealth to philanthropically do the same.

Another tidbit revealed in the "EXTREMIS" story that had profound implications was that Tony Stark had already come up with the ideafor a protective exosuit which he pitched to the military long before actually making the Mark I. He called it the "Iron Man Project" and Yinsen--the medical futurist who helped save his life--was present at a conference where he described the idea.

This explains why he could build the armor so quickly. A genius like Tony already knew how the exosuit had to work, so it was just a matter of constructing something whose plans he'd already designed.

When the Mark I made its debutin Tales of Suspense, Iron Man seemed like more of a horror character than a superhero, his iron-grey armor transforming him from a charismatic handsome playboy into a mechanical inhuman monster, a humuicular golem whose life was saved at the expense of humanity. When hereappeared in the next issue, the character actually scared away the people he was tryingto save.

RELATED: The 10 Most Impractical Marvel Costumes, Ranked

Wanting to be a symbol of hope instead of an object of fear, he repainted the Mark I with a new gold finish. Almost every future suit would include gold along with thesignature "hot rod red."

In recent stories about Iron Man, the character's origin has been retconned so that he was abducted in Afghanistan, but originally, Tony Stark wasn't in the Middle East at all. He was captured by guerrillas in Vietnam.

There are many reasons to update this origin. For one, the Vietnam War is now decades older than the in-universe age of Tony Stark (who seems to be in his early 40s). The original portrayal of Iron Man in Vietnam involved some really uncomfortable stereotypical depictions of Asian characters, heavy-handed anti-communist propaganda, and dated views on the war.

During the "Extremis" storyline, several key changes occurred, including the previously-mentioned update of Tony Stark's origins. The story explored how futuristsrely on major corporations and military contracts for funding. After being mortally wounded, Tony used the newly-made EXTREMISserum to rewrite his DNA, storing parts of the Iron Man suit in the hollows of his bones.

RELATED: 10 Times Tony Stark Became More Machine Than Man

This story marked the point where Tony Stark becamea true futurist, a superhero powered by his own inventions! A few years later, he would have to downgrade that technology.After storing sensitive information on his brain'shard drive, he began towipe his brain clean to keep that datafrom being accessed by the villainNorman Osborn. He couldn't operate his more advanced armors like that. However, even with half a brain, he could use the Mark I.

When Tony Stark took up his original Mark I while being hunted by Norman Osborn, he knew it was only a matter of time before the villain came after him. After all, Osborn was in charge of Earth's security at the time--a position that Starkhad previously held.

Osborn repurposed one of the more recent Iron Man suits to make a new identity for himself as Iron Patriot--the red, white, and blue warmonger who used the colors of American patriotism to legitimize his Stasi-esquegangsterism. When Iron Patriotfinally caught up with Iron Man, the hero tried fighting him off while wearing the antiquated Mark I. Surprisingly, the old suit held up for quite a while as it was assaulted with a full bombardment fromthe newer mech.

That Iron Man would build gadgets into his suit should surprise no one. However, in the Silver Age, the Mark I seemed less like a streamlined exosuit and more like something out of theInspector Gadget cartoons.

Some of thesegadgets included a miniature saw in his fingertips, a hose that shotoil, and a radio jamming device that both created noise interference andallowed Iron Man to hijack speaker systems to speak through them at a distance. While these were fun in the Silver Age, the comics are better for having moved past them.

NEXT: 10 Hidden Features Of Iron Man's Armor, Revealed

Tags:marvel,iron man

Next5 DC Heroes The Hulk Could Defeat (And 5 He Wouldn't Stand A Chance Against)

Read more:

Iron man: 10 Things Fans Never Knew About The Mark 1 Armor | CBR - CBR - Comic Book Resources

Incredible Growth of Testosterone Replacement Therapy Market Recent Study including Growth by 2026 – Health News Office

A Comprehensive research study conducted byKD Market Insightson Eye Testing Equipment Market- by Device {Slit Lamp, Biometer, Perimeter, Tonometer, Optical Coherence Tomography (OCT), Fundus Camera, Autorefractor and Keratometer, and Other Devices}, Application (General Examination, Glaucoma, Cataract, and Other Applications), and End User (Hospital, Eye Clinic, and Optometry Academic Institute) Global Opportunity Analysis and Industry Forecast, 2017-2025 report offers extensive and highly detailed historical, current and future market trends in the Global and regional/market. TheEye Testing Equipment Marketreport includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments.

The globaleye testing equipment marketwas valued at $2,638 million in 2017 and is expected to reach $3,914 million by 2025, registering aCAGR of 5.0%from 2018 to 2025. Ophthalmic diagnostic devices/eye testing equipment/optometry devices are used for detection and analysis of eye-related diseases such as refractive error, cataract, glaucoma, and diabetic retinopathy. These diagnostic devices are of utmost importance to provide proper treatment to the patients to avoid further damage to the vision or loss of vision.

Request for Sample @https://www.kdmarketinsights.com/sample/4184Considerable increase in the incidence of eye-associated disorders especially cataract and glaucoma across the globe has played a significant role in driving the growth of eye testing equipment market. Immediate treatment of people suffering from glaucoma is essential as glaucoma in severe cases may result in loss of vision permanently. This immediate attention is possible only when the patients undergo comprehensive eye examinations wherein eye testing devices are utilized for effective diagnosis. In addition, glaucoma is anticipated to be the leading cause of blindness among people in the age group of 60 years and above. Whereas, cataract is a condition wherein clouding of the lens occurs resulting in decreased vision, and its incidence has been on the rise over the years.

The globaleye testing equipment marketis segmented based on device, application, end user, and region. Based on device, the market is classified into slit lamp, biometer, perimeter, tonometer, optical coherence tomography (oct) scanner, fundus camera, autorefractor & keratometer, and other devices. The other devices include lensmeter, chart projector/visual acuity accessory/computerized visual acuity system, ophthalmoscope, and others. By application, it is categorized into general examination, glaucoma, cataract, and other applications. The end users covered in the study include hospital, eye clinic, and optometry academic institute. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERSThe study provides an in-depth analysis of the global eye testing equipment market with the current trends and future estimations to elucidate the imminent investment pockets.A comprehensive analysis of the factors that drive and restrict the market growth is provided.A comprehensive quantitative analysis of the industry is provided from 2017 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.An extensive analysis of the key segments of the industry helps understand the trends in eye testing equipment globally.Key players and their strategies are provided to understand the competitive outlook of the industry.

KEY MARKET SEGMENTSBy Device Slit Lamp Biometer Perimeter Tonometer Optical Coherence Tomography (OCT) Fundus Camera Autorefractor and Keratometer Other Devices

By Application General Examination Glaucoma Cataract Other Applications

By End User Hospital Eye Clinic Optometry Academic Institute

By RegionNorth America U.S. Canada MexicoEurope Germany France UK Italy Spain Rest of EuropeAsia-Pacific Japan China India Australia South Korea Rest of Asia-PacificLAMEA Brazil Saudi Arabia South Africa Rest of LAMEA

KEY MARKET PLAYERS Carl Zeiss Metall Zug AG (Haag Streit) Topcon Corporation Nidek Co., Ltd. Escalon Novartis Canon Essilor Heine Optotechnik Luneau Technology

The other players in the value chain include (profiles not included in the report) Heidelberg Engineering GmBH Huvitz BON Optic Reichert Technologies Potec Visionix Tomey Corporation LuxVision

Browse Full Report with TOC @https://www.kdmarketinsights.com/product/eye-testing-equipment-market-amrTable of Contents:

CHAPTER 1: INTRODUCTION1.1. Report description1.2. Key benefits for stakeholders1.3. Key market segments1.4. Research methodology1.4.1. Secondary research1.4.2. Primary research1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW3.1. Market definition and scope3.2. Key findings3.2.1. Top investment pockets3.3. Porters five forces analysis3.4. Market share analysis, 20173.5. Market dynamics3.5.1. Drivers3.5.1.1. Rising prevalence of eye diseases across the globe3.5.1.2. Increase in the technological advancements in the field of ophthalmological diagnostics3.5.1.3. Increasing government initiatives to control visual impairment3.5.2. Restraints3.5.2.1. Dearth of skilled professionals3.5.2.2. Low accessibility to eye care in low income countries3.5.3. Opportunity3.5.3.1. Emerging nations offer profitable opportunities for eye testing equipment manufacturers

CHAPTER 4: EYE TESTING EQUIPMENT MARKET, BY DEVICE4.1. Overview4.1.1. Market size and forecast4.2. Slit Lamps4.2.1. Key trends and opportunities4.2.2. Market size and forecast4.2.3. Market analysis, by country4.3. Biometers4.3.1. Key trends and opportunities4.3.2. Market size and forecast4.3.3. Market analysis, by country4.4. Perimeters4.4.1. Key trends and opportunities4.4.2. Market size and forecast4.4.3. Market analysis, by country4.5. Tonometers4.5.1. Key trends and opportunities4.5.2. Market size and forecast4.5.3. Market analysis, by country4.6. Optical Coherence Tomography (OCT)4.6.1. Key trends and opportunities4.6.2. Market size and forecast4.6.3. Market analysis, by country4.7. Fundus Cameras4.7.1. Key trends and opportunities4.7.2. Market size and forecast4.7.3. Market analysis, by country4.8. Autorefractors and Keratometers4.8.1. Key trends and opportunities4.8.2. Market size and forecast4.8.3. Market analysis, by country4.9. Other Devices4.9.1. Key trends and opportunities4.9.2. Market size and forecast4.9.3. Market analysis, by country

CHAPTER 5: EYE TESTING EQUIPMENT MARKET, BY APPLICATIONS5.1. Overview5.1.1. Market size and forecast5.2. General Eye Examinations5.2.1. Market size and forecast5.2.2. Market analysis, by country5.3. Glaucoma5.3.1. Market size and forecast5.3.2. Market analysis, by country5.4. Cataract5.4.1. Market size and forecast5.4.2. Market analysis, by country5.5. Other Applications5.5.1. Market size and forecast5.5.2. Market analysis, by country

CHAPTER 6: EYE TESTING EQUIPMENT MARKET, BY END USER6.1. Overview6.1.1. Market size and forecast6.2. Hospitals6.2.1. Market size and forecast6.2.2. Market analysis, by country6.3. Eye Clinics6.3.1. Market size and forecast6.3.2. Market analysis, by country6.4. Optometry Academic Institutes6.4.1. Market size and forecast6.4.2. Market analysis, by country

CHAPTER 7: EYE TESTING EQUIPMENT MARKET, BY REGION7.1. Overview7.1.1. Market size and forecast7.2. North America7.2.1. Key trends and opportunities7.2.2. North America market size & forecast, by country7.2.2.1. U.S. market size & forecast, by device7.2.2.2. U.S. market size & forecast, by application7.2.2.3. U.S. market size & forecast, by end user7.2.2.4. Canada market size & forecast, by device7.2.2.5. Canada market size & forecast, by application7.2.2.6. Canada market size & forecast, by end user7.2.2.7. Mexico market size & forecast, by device7.2.2.8. Mexico market size & forecast, by application7.2.2.9. Mexico market size & forecast, by end user7.2.3. North America market size & forecast, by device7.2.4. North America market size & forecast, by application7.2.5. North America market size & forecast, by end user7.3. Europe7.3.1. Key trends and opportunities7.3.2. Europe market size & forecast for eye testing equipment market, by country7.3.2.1. Germany market size & forecast, by device7.3.2.2. Germany market size & forecast, by application7.3.2.3. Germany market size & forecast, by end user7.3.2.4. France market size & forecast, by device7.3.2.5. France market size & forecast, by application7.3.2.6. France market size & forecast, by end user7.3.2.7. UK market size & forecast, by device7.3.2.8. UK market size & forecast, by application7.3.2.9. UK market size & forecast, by end user7.3.2.10. Italy market size & forecast, by device7.3.2.11. Italy market size & forecast, by application7.3.2.12. Italy market size & forecast, by end user7.3.2.13. Spain market size & forecast, by device7.3.2.14. Spain market size & forecast, by application7.3.2.15. Spain market size & forecast, by end user7.3.2.16. Rest of Europe market size & forecast, by device7.3.2.17. Rest of Europe market size & forecast, by application7.3.2.18. Rest of Europe market size & forecast, by end user7.3.3. Europe market size & forecast, by device7.3.4. Europe market size & forecast, by application7.3.5. Europe market size & forecast, by end user7.4. Asia-Pacific7.4.1. Key trends and opportunities7.4.2. Asia-Pacific market size & forecast, by country7.4.2.1. Japan market size & forecast, by device7.4.2.2. Japan market size & forecast, by application7.4.2.3. Japan market size & forecast, by end user7.4.2.4. China market size & forecast, by device7.4.2.5. China market size & forecast, by application7.4.2.6. China market size & forecast, by end user7.4.2.7. India market size & forecast, by device7.4.2.8. India market size & forecast, by application7.4.2.9. India market size & forecast, by end user7.4.2.10. Australia market size & forecast, by device7.4.2.11. Australia market size & forecast, by applicationContinue.

Check for Discount @https://www.kdmarketinsights.com/discount/4184

About Us:

KD Market Insightsis one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends. Our in-house research experts have a wealth of knowledge in their respective domains. With KD Market Research, you always have the choice of getting customized report free of cost (up to 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.Our clients list includes various Fortune 500 companies and leading advisory firms.

Contact Us:KD Market Insights90 State Street, Albany,New York, USA 12207+1 (518) 300-1215Email:[emailprotected]Website:www.kdmarketinsights.comRead More News:https://foodcourt894109857.wordpress.com/https://automotiveindustry9.blogspot.com/

Read the original post:
Incredible Growth of Testosterone Replacement Therapy Market Recent Study including Growth by 2026 - Health News Office

Insurer Can’t Blame Drug Cos. For Its Inaction, 7th Circ. Told – Law360

Law360, Chicago (November 6, 2019, 2:28 PM EST) -- A Seventh Circuit judge on Wednesday pushed Medical Mutual of Ohio to address why it waited until July 2016 to take steps to limit which testosterone replacement drugs the insurer would cover, two years after the U.S. Food and Drug Administration flagged potential cardiovascular risks associated with the drugs.

During oral arguments, Medical Mutual urged the Seventh Circuit to revive its Racketeer Influenced and Corrupt Organizations Act suit against AbbVie and other makers of testosterone replacement drugs, or TRTs, saying they misrepresented those drugs as being safe and effective for a host of symptoms related to normal male aging.

But U.S....

In the legal profession, information is the key to success. You have to know whats happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

TRY LAW360 FREE FOR SEVEN DAYS

Read the original here:
Insurer Can't Blame Drug Cos. For Its Inaction, 7th Circ. Told - Law360

Testosterone Replacement Therapy Market Published by Leading Research Firm – Maxi Wire

The globaltestosterone replacement therapy marketrides on the back of technology. As consumer focus shifts from access to comfort, players in the market for testosterone replacement therapy are looking at new opportunities to capitalize on the potential. This exclusive report from Transparency Market Research will take you through an extensive analysis of every aspect in the testosterone replacement therapy market that is critical for defining your success strategy. It offers prudent information on markets under currents, trends that will open new doors, factors that will remain important, challenges that need to be overcome, prevailing competition in the market, and the geographical landscape.

Based on a tested and proven research methodology, our research analysts bring to you fact-checked information. Besides presenting the current market figures, our analysts provide you with accurate forecasts that can be the game-changer for your winning strategies for tomorrow. On the other hand, our reports also offer tailor-made insights. Further, our reports are packed with experts viewpoints which are transcribed from interviews conducted by our analysts.

For Right Perspective & Competitive Insights,Request For A Sample Here

For every market, information on leading players can be the difference between success and failure, be it a prominent brand or not. Our reports cover every significant players in the global testosterone replacement therapy market providing information about the company profile, products, winning strategies and market revenues. Not just that, TMR also provides information on the competitive landscape, helping you understand what impacted in one company being the market leader and others not. It also explains on the companies imperatives that define their success in the global market for testosterone replacement therapy.

Healthcare, unlike most industries, is typical of the region. Humans have multiple races and hence their genetic makeups are different. As a result, one condition has different impacts depending on the region. Therefore, information on how consumer requirements are different in regional landscape of the global testosterone replacement therapy is provided her in the report. Further, the economic capabilities of a country has a huge impact on healthcare infrastructure. TMRs report analysis the current economic scenario and also brings to you information on affordability during the coming years.

To Clarify Your Doubts About The Report,Request A Brochure Here

From market share to region-specific strategies, the report covers it all. At the same time, players in the testosterone replacement therapy market who are looking to expand might want to assess the potential of a prospective region. Our reports can provide you with custom-made insights for specific regions in the global testosterone replacement therapy market. The geographical analysis also covers regions-specific factors that could turn out to be hurdle for growth in the coming years.

Original post:
Testosterone Replacement Therapy Market Published by Leading Research Firm - Maxi Wire

Testosterone Replacement Therapy Market Top key Players, Size, Share, Demand, Opportunities And Forecasts To 2025 – Weekly Spy

Testosterone Replacement Therapy Market primary data collection was achieved by interviewing the retailers and the consumers. The interviews were conducted through one to one structured questionnaire supervision.

Global Testosterone Replacement Therapy Market report provides an in-depth analysis of all market dynamics including drivers and restraints, and trends and opportunities. Important factors supporting growth across various is also provided. Using the industrial figures, the market finds growth figures between the forecast timespan.

In order to present an executive-level model of the market and its future perspectives, Testosterone Replacement Therapy Market report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Request Exclusive Free Sample PDF Of This Report At https://dataintelo.com/request-sample/?reportId=110389

Major Players included in this report are as follows

AbbVie Endo International Eli lilly Pfizer Actavis (Allergan) Bayer Novartis Teva Mylan Upsher-Smith Ferring Pharmaceuticals Kyowa Kirin Acerus Pharmaceuticals

Testosterone Replacement Therapy Market can be segmented into Product Types as

Gels Injections Patches Other

Testosterone Replacement Therapy Market can be segmented into Applications as

Hospitals Clinics Others

Testosterone Replacement Therapy Market: Regional analysis includes:Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)North America (United States, Mexico, and Canada.)South America (Brazil etc.)The Middle East and Africa (GCC Countries and Egypt.)

The research provides answers to the following key questions: What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Testosterone Replacement Therapy? Who are the global key manufacturers of Testosterone Replacement Therapy industry? How are their operating situation (capacity, production, price, cost, gross and revenue)? What are the types and applications of Testosterone Replacement Therapy? What is the market share of each type and application? What are the upstream raw materials and manufacturing equipment of Testosterone Replacement Therapy? What is the manufacturing process of Testosterone Replacement Therapy? Economic impact on Testosterone Replacement Therapy industry and development trend of Testosterone Replacement Therapy industry. What will the Testosterone Replacement Therapy market size and the growth rate be in 2025? What are the key factors driving the global Testosterone Replacement Therapy industry? What are the key market trends impacting the growth of the Testosterone Replacement Therapy market? What is the Testosterone Replacement Therapy market challenges to market growth? What are the Testosterone Replacement Therapy market opportunities and threats faced by the vendors in the global Testosterone Replacement Therapy market?

For More Information on this report, Request Inquiry At https://dataintelo.com/enquiry-before-buying/?reportId=110389

Testosterone Replacement Therapy Market track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, research and developments, with respect to the current market size and future prospective.

For Best Discount on purchasing this report, Visit https://dataintelo.com/ask-for-discount/?reportId=110389

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Read More Trending News at Top Special Reports

Contact Info Name Alex MathewsPhone +1 909 545 6473Email sales@dataintelo.comWebsite https://dataintelo.comAddress 500 East E Street, Ontario, CA 91764, United States.

Continue reading here:
Testosterone Replacement Therapy Market Top key Players, Size, Share, Demand, Opportunities And Forecasts To 2025 - Weekly Spy

Go or no go? Agile and Lipocine hope to make it third time lucky – Vantage

After some huge US approvals in recent months, November is shaping up to be quieter. There are no decisions on future blockbusters set for next month, Vantages regular PDUFA analysis shows.

However, some of the upcoming verdicts will still be a big deal for the companies involved. This includes Agile Therapeutics and Lipocine, which hope to bounce back from complete response letters for the Twirla contraceptive patch and the testosterone replacement therapy Tlando respectively.

Twirla's chances of getting approved got a boost yesterday, with an FDA advisory committee voting 14-1 that the benefits of the projects outweigh its risks an unexpected outcome given scathing briefing documentsreleased on Monday. The agency questioned the patch's efficacy, thoughAgile put unimpressive results from the pivotal Secure trial down to a high number of obese participants, in whom contraceptives do not work as well.

The FDA questioned Twirla's efficacy even in non-obese women, however, and also raised doubts about whether the project is a low-dose, and therefore potentially safercontraceptive, as Agile has claimed. Shares in the company recovered today after slumping on the briefing docs, but investors' wild ride might not be over yet.

Meanwhile, Lipocine will hope that an ambulatory blood pressure study will answer questions raised in the FDAs May 2018 CRL. The company believes that Tlando, an oral therapy, will have an edge over injectable testosterone products. Another oral contender got the FDA nod earlier this year, Clarus Therapeutics Jatenzo, andLipocine is embroiled in a legal wrangle with Clarus over intellectual property.

A project that should get a smoother ride is Shionogis S-649266, or cefiderocol, a novel antibiotic targeting Gram-negative pathogens. The project recently got an adcom thumbs up, with panellists voting14-2 in favour ofapproval for patients with complicated urinary tract infections and limited or no alternative treatment options.

The project has also shown promise in pneumonia. Still, as with many antibiotics, especially those saved for drug-resistant infections, succeeding commercially will be trickier.

Meanwhile, Redhill Biopharmas Talicia, which combines two antibiotics and a proton pump inhibitor, is awaiting a verdict in Helicobacter pylori infection. It has a good shot after a positive result in the Eradicate Hp2 trial, and a recent tie-up with Cosmo Pharmaceuticals should also give Redhill sufficient funds for launch.

However, sales expectations are not huge, with EvaluatePharma consensus predicting $27m in 2024.

Supplements

As for potential supplementary approvals, Lilly and Boehringer hope to get cardiovascular data on the label of their DPPIV inhibitor Tradjenta. However, the product has only shown noninferiority to placebo in the Carmelina study; with other diabetes drugs like the SGLT2s and GLP1s showing cardioprotective effects, the DPPIV class has been put in the shade.

Other decisions, including a verdict on Pfizers Humira biosimilar, continue to be expected sometime in the fourth quarter.

The biggest regulatory event of November is not an approval but rather an advisory committee meeting, for Amarins Vascepa. On November 14 panellists will consider the products expanded use for the reduction of cardiovascular events in patients with high triglycerides; the FDA had previously been expected to make a call here in September.

EvaluatePharma consensus forecasts 2024 Vascepa sales of $2.2bn, but Leerink analysts believe that, if the drug does get expanded approval, US revenues could exceed $4bn.

Original post:
Go or no go? Agile and Lipocine hope to make it third time lucky - Vantage

Testosterone Replacement Therapy Market 2019 to 2024 With Top Countries Data : Opportunities, Industry Trends and Policies by Regions and Companies -…

The worldwide market for Testosterone Replacement Therapy is expected to grow at a CAGR of roughly -4.2% over the next five years, will reach 1410 million US$ in 2024, from 1820 million US$ in 2019, according to a new Reserach Report

Testosterone Replacement Therapy Market2019 Research report contains a qualified and in-depth examination of Testosterone Replacement Therapy Market. At first, the report provides the current Testosterone Replacement Therapy business situation along with a valid assessment of the Testosterone Replacement Therapy business. Testosterone Replacement Therapy report is partitioned based on driving Testosterone Replacement Therapy players, application and regions. The progressing Testosterone Replacement Therapy economic situations are additionally discovered in the report.

Short Description About Testosterone Replacement Therapy Market :

Testosterone replacement therapy (TRT) is a class of hormone replacement therapy in which androgens, often testosterone, are replaced. Testosterone replacement therapy (TRT) is an FDA-approved medical treatment for men of any age who have low testosterone, a hormone necessary for male sexual development.

Get Sample PDF of reporthttps://www.360researchreports.com/enquiry/request-sample/13836798

The research covers the current market size of the Testosterone Replacement Therapy market and its growth rates based on 5-year records with company outline ofKey players/manufacturers:

Scope Of The Report :

Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.The global average price of testosterone replacement therapy is in the decreasing trend, from 45.4 USD/Unit in 2012 to 34.9 USD/Unit in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.The classification of testosterone replacement therapy includes gels, injections, patches and other types, and the proportion of gels in 2016 is about 72%.Testosterone replacement therapy is widely sold in hospitals, clinics and other field. The most proportion of testosterone replacement therapy is sold in clinics, and the consumption proportion is about 43%.North America region is the largest supplier of testosterone replacement therapy, with a production market share nearly 86% in 2016. Europe is the second largest supplier of Testosterone Replacement Therapy, enjoying production market share nearly 9.9% in 2016.North America is the largest consumption place, with a consumption market share nearly 83% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 12%. Market competition is intense. AbbVie, Endo International, Eli Lilly, Pfizer, Actavis (Allergan)Bayer, etc. are the leaders of the industry. The top five players together held about 80% of the market in the same year and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry. The worldwide market for Testosterone Replacement Therapy is expected to grow at a CAGR of roughly -4.2% over the next five years, will reach 1410 million US$ in 2024, from 1820 million US$ in 2019, according to a new research study.This report focuses on the Testosterone Replacement Therapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/13836798

Report further studies the Testosterone Replacement Therapy market development status and future trend across the world. Also, it splits Testosterone Replacement Therapy market by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Major Applications are as follows:

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Testosterone Replacement Therapy in these regions, from 2014 to 2024, covering

The Testosterone Replacement Therapy market report provides answers to the following key questions:

Purchase this report (Price 3480 USD for a single-user license) https://www.360researchreports.com/purchase/13836798

Major Points from Table of Contents:

1 Market Overview1.1 Testosterone Replacement Therapy Introduction1.2 Market Analysis by Type1.3 Market Analysis by Applications1.4 Market Dynamics1.4.1 Market Opportunities1.4.2 Market Risk1.4.3 Market Driving Force

2.Manufacturers Profiles

2.4.1 Business Overview2.4.2 Testosterone Replacement Therapy Type and Applications2.4.2.1 Product A2.4.2.2 Product B

3.Global Testosterone Replacement Therapy Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

3.1 Global Testosterone Replacement Therapy Sales and Market Share by Manufacturer (2017-2018)3.2 Global Testosterone Replacement Therapy Revenue and Market Share by Manufacturer (2017-2018)3.3 Market Concentration Rate3.3.1 Top 3 Testosterone Replacement Therapy Manufacturer Market Share in 20183.3.2 Top 6 Testosterone Replacement Therapy Manufacturer Market Share in 20183.4 Market Competition Trend

4 Global Testosterone Replacement Therapy Market Analysis by Regions

4.1 Global Testosterone Replacement Therapy Sales, Revenue and Market Share by Regions4.1.1 Global Testosterone Replacement Therapy Sales and Market Share by Regions (2014-2019)4.1.2 Global Testosterone Replacement Therapy Revenue and Market Share by Regions (2014-2019)4.2 North America Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.3 Europe Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.4 Asia-Pacific Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.6 South America Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.6 Middle East and Africa Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)

6 Testosterone Replacement Therapy Market Forecast (2019-2024)6.1 Global Testosterone Replacement Therapy Sales, Revenue and Growth Rate (2019-2024)6.2 Testosterone Replacement Therapy Market Forecast by Regions (2019-2024)6.3 Testosterone Replacement Therapy Market Forecast by Type (2019-2024)6.3.1 Global Testosterone Replacement Therapy Sales Forecast by Type (2019-2024)6.3.2 Global Testosterone Replacement Therapy Market Share Forecast by Type (2019-2024)6.4 Testosterone Replacement Therapy Market Forecast by Application (2019-2024)6.4.1 Global Testosterone Replacement Therapy Sales Forecast by Application (2019-2024)6.4.2 Global Testosterone Replacement Therapy Market Share Forecast by Application (2019-2024)

6.Sales Channel, Distributors, Traders and Dealers6.1 Sales Channel6.1.1 Direct Marketing6.1.2 Indirect Marketing6.1.3 Marketing Channel Future Trend6.2 Distributors, Traders and Dealers

7. Research Findings and Conclusion

8. Appendix8.1 Methodology8.2 Data Source

Continued..

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us:Name: Mr. Ajay MoreEmail: [emailprotected]Organization: 360 Research ReportsPhone: +44 20 3239 8187/ +14242530807

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Testosterone Replacement Therapy Market 2019 to 2024 With Top Countries Data : Opportunities, Industry Trends and Policies by Regions and Companies

See the article here:
Testosterone Replacement Therapy Market 2019 to 2024 With Top Countries Data : Opportunities, Industry Trends and Policies by Regions and Companies -...

Male Hypogonadism Market Expand at the Fastest CAGR of 3.7% Throughout the Forecast Quantity 2017-2026 – Zebvo

According to Persistence Market Researchs new report, globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceed US$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally. Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period. Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Nature of global male hypogonadism market has been observed to be highly competitive. This can be mainly attributed to occupancy of many small as well as large suppliers. New companies entering the male hypogonadism market are leveraging opportunities related to treatment developments and innovations. Strategic alliances are likely to remain strong among vendors for producing and marketing drugs worldwide, thereby increasing their market reach. Active market players listed by PMRs report include Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Bayer AG, Endo International Plc., Allergan Plc., Ferring, Finox Biotech, AbbVie Inc., Eli Lilly and Company Ltd., Teva Pharmaceutical Industries Ltd., and IBSA Institut Biochimque.

Go here to read the rest:
Male Hypogonadism Market Expand at the Fastest CAGR of 3.7% Throughout the Forecast Quantity 2017-2026 - Zebvo

Testosterone Replacement Therapy Market Outlook: Heading To the Clouds – Daily Market Insight

Europe Testosterone Replacement Therapy study will help you investigate a detailed division of the market by the end user/industry, by best in class product type and by geography with creation, income, utilization, export & import data in these areas, crunching historical data along with primaries and opinion leaders and industry experts interview and estimate with detailed driving factors for forcasted period.

Get Sample Report PDF With More Details And Graph @https://www.htfmarketreport.com/sample-report/1631438-europe-testosterone-replacement-therapy-market-1The Europe Testosterone Replacement Therapy is relied upon to come to an expected $XX.X billion by 2025 and it is a gauge to develop at a CAGR of X.X% for forecast period. This report centers around top makers in the Europe Testosterone Replacement Therapy, with generation, value, income, and market share for every producer/manufacturers.

Top Testosterone Replacement Therapy Manufacturers:AbbVie, Allergan, Eli Lilly, Endo International, Acerus Pharmaceutical Corporation, Antares Pharma, Bayer HealthCare Pharmaceuticals, Bedford Labs, Clarus Therapeutics, Ferring Pharmaceuticals, Forendo Pharma, Juniper Pharmaceuticals, Lipocine, MetP Pharma, Mylan, Pfizer, ProStrakan, Repros Therapeutics, Sandoz, TesoRx & Teva Pharmaceuticals.Testosterone Replacement Therapy Report Focusing By Types:, Gels, Injectables & Patches

Testosterone Replacement Therapy Report Focusing By Applications:Hospitals & Clinics

Testosterone Replacement Therapy Report Focusing By Regions:Germany, France, UK, Russia, Italy, Spain & Benelux

For Detail View Of TOC (Table Of Content) @https://www.htfmarketreport.com/reports/1631438-europe-testosterone-replacement-therapy-market-1Testosterone Replacement Therapy Report shows a detailed overview of the market by strategy for study, mix, and data evaluated from different sources. The pros have presented the various appearances of the market with a particular, base on recognizing Testosterone Replacement Therapy business influencers.

Have Any Query? Ask Our Expert @https://www.htfmarketreport.com/enquiry-before-buy/1631438-europe-testosterone-replacement-therapy-market-1This Report Will Give a Nitty-Gritty Evaluation of Significantly Accompanying:

Item outline and extent of Europe Testosterone Replacement TherapySignificant players in the Europe Testosterone Replacement Therapy Market.Europe Testosterone Replacement Therapy players/providers Profiles and Sales information.Testosterone Replacement Therapy Marketing procedure examination and improvement patterns.Testosterone Replacement Therapy Market impact factor examination.Developing specialty fragments and local Testosterone Replacement Therapy markets.An experimental evaluation of the direction of the Testosterone Replacement Therapy.Real changes in Testosterone Replacement Therapy elements/ sub industry segments.Chronicled, present, and imminent size of the Testosterone Replacement Therapy from the point of view of both revenue and sales volume and average price.

It is vital for an organization to have the capacity to catch the mindshare of their gathering of people as it is characteristic for an organization which is planning to see a development in the Europe Testosterone Replacement Therapy. This is conceivable through a knowledgeable network administration and develops an advertising plan for the Europe Testosterone Replacement TherapyIndustry.

Buy this research report @https://www.htfmarketreport.com/buy-now?format=1&report=1631438Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218sales@htfmarketreport.com

Connect with us atLinkedIn|Facebook|Twitter

Original post:
Testosterone Replacement Therapy Market Outlook: Heading To the Clouds - Daily Market Insight

After Gaining 33% in 60 Days, AbbVie Beats Third-Quarter Earnings Expectations (NYSE:ABBV) – Stock Investor

After its stock gained a third of its value over the past 60 days, AbbVie, Inc. (NYSE:ABBV) beat revenue and earnings expectations and obtained potential fuel that may allow it to extend its current share price uptrend.

The companys share price exhibited steady growth and more than doubled from its initial public opening (IPO) price of $34.40 to more than $75 by August 2017. After a brief spike to nearly $125 over the next five months, the share price reversed direction and gave back those quick gains by the beginning of 2019.

However, the chart below illustrates that the share price was still at its long-term uptrend in January 2019. However, after dropping further, the share price has been rising steadily since mid-August 2019 and the positive results from the current quarterly report should continue to power the current share price recovery.

Released on November 1, AbbVies report for the third quarter of 2019 which ended on September 30, 2019 revealed a 3% increase in worldwide net revenues to $8.48 billion. Diluted earnings per share (EPS) were $1.26. The adjusted EPS of $2.33 was nearly 9% above the $2.14 adjusted EPS from the same period last year and beat analysts earnings expectations of $2.29 by 1.75%. After missing earnings estimates by 2% in the last quarter of 2018, AbbVie managed to beat earnings expectations in the last three consecutive quarters and four times in the last five periods.

The companys current $1.07 quarterly dividend is 11.5% higher than the companys $0.96 payout from the same quarter last year. This new quarterly payout corresponds to a $4.28 annualized distribution. Using the $79.55 share price as of closing on October 31, 2019, the current payout is equivalent to a 5.38% forward dividend yield. This is 32.5% above the companys own 4.06% yield average over the past five years.

Additionally, AbbVies current yield level is the highest among the companys peers in the Major Drug Manufacturers market segment. Furthermore, AbbVies current yield is at least 20% higher than the segments only other yields in excess of 4% Takeda Pharmaceutical Co Ltd (NYSE:TAK) at 4.51% and GlaxoSmithKline Plc (NYSE:GSK) at 4.37%. As the segments top value, AbbVies current yield is nearly triple the segments 1.8% simple average, as well as nearly double the 2.8% average yield of the segments only dividend paying companies. Furthermore, in a sector that is renowned for its low dividend payouts, AbbVies current yield is nearly 10-fold higher than the 0.52% simple yield average of the entire Health Care sector.

As a separate legal entity, AbbVies current streak of consecutive annual dividend hikes only goes back six years. However, the companys history of dividend payouts as part of Abbot Labs goes back several decades. In 2013 the year of the divestiture from Abbott Laboratories the two companies paid individual dividends. However, the sum of the two payouts was higher than Abbott Laboratories total dividend payout over the previous year. Furthermore, both companies have continued to hike their respective annual dividends every year since 2013.

Therefore, we can give credit for the past dividend hikes to both companies and consider the annual dividend hikes since 2012 to be a continuation of the previous streak. Under that assumption, AbbVie has boosted its annual dividend payout for the past 46 consecutive years. Since AbbVie is a component of the S&P 500 Index and meets all the other market capitalization, liquidity and trading volume requirements, we can include the company as a part of the S&P 500 Dividend Aristocrats group.

Even disregarding the dividend distributions that were delivered prior to 2013, AbbVie has enhanced its annual dividend distribution amount by nearly 170% just over the past six years that it has been its own business entity. That level of advancement corresponds to an average growth rate of nearly 18% per year.

The share price entered the trailing 12-month period by riding the downtrend that began in January 2018. After passing through its 52-week low of $94.27 on November 30, 2018, the share price declined by nearly 50% before reaching the 52-week low of $62.98 on August 15, 2019.

However, since reversing its trend in mid-August, the share price has recovered more than half of its losses since the November peak and closed on October 31, 2019, at $79.55. This was flat with the price level of one year ago and 26% higher than the 52-week low from August. Furthermore, the share price surged 3.5% on positive financial results in just the first hour of trading on Nov. 1. The share price trailed off a little afterwards even though it held on to a 2.5% gain as of noon on the same day.

With the share price at last years levels, dividend income payouts have contributed all of the total gains of approximately 5% over the trailing 12 months. However, capital gains have contributed most of the total gains of more than 60% over the past three years.

Headquartered in North Chicago, Illinois, and founded when Abbott Labs (NYSE:ABT) divested its proprietary pharmaceutical business in 2013, AbbVie Inc. discovers, develops, manufactures and sells pharmaceutical products. The most prominent pharmaceutical brands in the companys current portfolio are HUMIRA for the treatment of autoimmune diseases, IMBRUVICA for the treatment of patients with chronic lymphocytic leukemia and VIEKIRA PAK for the treatment of adults with hepatitis C. Additionally, AbbVie offers pharmaceutical treatments for HIV, hypothyroidism, prostate cancer, endometriosis, anemia, Parkinsons disease and multiple sclerosis, as well as treatments for testosterone replacement therapy and pancreatic enzyme therapy for exocrine pancreatic insufficiency.

Ned Piplovicis the assistant editor of website content at Eagle Financial Publications. He graduated from Columbia University with a Bachelors degree in Economics and Philosophy. Prior to joining Eagle, Ned spent 15 years in corporate operations and financial management. Ned writes forwww.DividendInvestor.comandwww.StockInvestor.com.

See the rest here:
After Gaining 33% in 60 Days, AbbVie Beats Third-Quarter Earnings Expectations (NYSE:ABBV) - Stock Investor

Microprotein ID’d Affecting Protein Folding and Cell Stress Linked to Diseases Like Huntington’s, Study Finds – Huntington’s Disease News

PIGBOS a newly discovered mitochondrial microprotein involved in a cellular stress-response mechanism called unfolded protein response (UPR) might be a treatment target for neurodegenerative diseases likeHuntingtons, a study suggests.

The study, Regulation of the ER stress response by a mitochondrial microprotein, was published in the journal Nature Communications.

Maintenance of protein balance including the production, shaping (folding), and degradation of proteins is essential for a cells function and survival.

Dysfunction in protein balance has been associated with the build-up of toxic protein aggregates and the development of neurodegenerative diseases, including Alzheimers, Parkinsons, and Huntingtons disease.

The endoplasmic reticulum (ER) is a key cellular structure in the production, folding, modification, and transport of proteins. Excessive amounts of unfolded or misfolded proteins (proteins with abnormal 3D structures) in the ER results in ER stress, and the activation of the unfolded protein response (UPR) stress response mechanism, which acts to mitigate damage caused by this protein build-up.

UPR promotes the reduction of protein production and an increase in protein folding and degradation of unfolded proteins in the ER. If this fails to restore cellular balance and prolongs the activation of UPR, cell death is induced.

UPR dysfunction contributes to accumulation of key disease-related proteins, and thus plays an essential role in the [development] of many neurodegenerative disorders, including Alzheimers disease, Parkinsons disease, and Huntingtons disease, the researchers wrote.

During UPR, mitochondria the cells powerhouses are known to provide energy for protein folding in the ER and to activate cell death pathways if the cellular balance is not restored. However, how mitochondria and the ER communicate in this context remains unclear.

Researchers at the Salk Institute for Biological Studies, in California, discovered a mitochondrial microprotein, called PIGBOS, that regulates UPR at the sites of contact between mitochondria and the ER.

While the average human protein contains around 300 amino acids (the building blocks of proteins), microproteins have less than 100 amino acids. Microproteins were only recently found to be functional and important in the regulation of several cellular processes.

By conducting protein-binding experiments, the team found that the 54-aminoacidmicroprotein PIGBOS, present in the outer membrane of mitochondria, interacts with a protein called CLCC1 at the ER-mitochondria contact sites.

CLCC1 whose low levels werepreviously associated with increased UPR and neurodegeneration is found at the portion of the ER that contacts the mitochondria, called mitochondria-associated ER membrane.

Further analyses showed that inducing ER stress in cells genetically modified to lack CLCC1 or PIGBOS increased the levels of UPR-related proteins, while the opposite effect was observed in cells overproducing PIGBOS. Lower levels of PIGBOS were also associated with greater cell death.

Researchers noted that these findings suggest that loss of PIGBOS increases cellular sensitivity to ER stress, which in turn increases [cell death] and links PIGBOS levels to the ability of cells to survive stress, emphasizing that modulating PIGBOS levels can in turn modulate cellular sensitivity towards ER stress.

Results also showed that PIGBOSs UPR regulation is dependent on its interaction with CLCC1, and that modulating the number of ER-mitochondria contacts regulates the levels of PIGBOS-CLCC1 interactions.

These data identified PIGBOS as a [previously] unknown mitochondrial regulator of UPR, and the only known microprotein linked to the regulation of cell stress or inter-organelle signaling, the team emphasized.

These findings may help in developing treatment approaches targeting ER stress and cell death.

Given the importance of UPR in biology and disease, future studies on PIGBOSs role in UPR should afford additional insights and may provide methods for regulating this pathway for therapeutic applications, the researchers concluded.

Total Posts: 79

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Excerpt from:

Microprotein ID'd Affecting Protein Folding and Cell Stress Linked to Diseases Like Huntington's, Study Finds - Huntington's Disease News

IBM vs. Google and the Race to Quantum Supremacy – Citizen Truth

Though IBM contests Googles claim of quantum supremacy, it concedes that it passed an important milestone. For the science of computing, that is all that matters.

Googles quantum supremacy claim has now been disputed by its close competitor IBM. Not because Googles Sycamore quantum computers calculations are wrong, but because Google had underestimated what IBMs Summit, the most powerful supercomputer in the world, could do. Meanwhile, Googles paper, which had accidentally been leaked by a NASA researcher, has now been published in the prestigious science journal Nature. Googles claims are official now, and therefore can be examined in the way any new science claim should be examined: skeptically until all the doubts are addressed.

Previously, I have covered what quantum computing is, and in this article, I will move on to the key issue of quantum supremacy, the claim that IBM has challenged and what it really means. IBM concedes that Google has achieved an important milestone, but does not accept that it has achieved quantum supremacy.

IBM refuted Googles claim around the same time as Googles Nature paper was published. Google had claimed that IBMs supercomputer, Summit, would take 10,000 years to solve the problem Googles Sycamore had solved in a mere 200 seconds. IBM showed that Summit, with clever programming and using its huge disk space, could actually solve the problem in only 2.5 days. Sycamore still beat Summit on this specific problem by solving it 1,100 times faster, but not 157 million times faster, as Google had claimed. According to IBM, this does not establish quantum supremacy as that requires solving a problem a conventional computer cannot solve in a reasonable amount of time. Two and a half days is reasonable, thereforeaccording to IBMquantum supremacy is yet to be attained.

The original definition of quantum supremacy was given by John Preskill, on which he now has second thoughts. Recently he wrote, supremacy, through its association with white supremacy, evokes a repugnant political stance. The other reason is that the word exacerbates the already overhyped reporting on the status of quantum technology.

Regarding IBMs claim that quantum supremacy has not yet been achieved, Scott Aaronson, a leading quantum computing scientist, wrote that though Google should have foreseen what IBM has done, it does not invalidate Googles claim. The key issue is not that Summit had a special way to solve the specific quantum problem Google had chosen, but that Summit cannot scale: if Googles Sycamore goes from 53 to 60 qubits, IBM will require 33 Summits; if to 70 Qubits, a supercomputer the size of a city!

Why does Summit have to increase at this rate to match Sycamores extra qubits? To demonstrate quantum supremacy, Google chose the simulation of quantum circuits, which is similar to generating a sequence of truly random numbers. Classical computers can produce numbers that appear to be random, but it is a matter of time before they will repeat the sequence.

The resourcesdisk space, memory, computing powerclassical computers require to solve this problem, in a reasonable time, increase exponentially with the size of the problem. For quantum computers, adding qubits linearlymeaning, simply adding more qubitsincreases computing capacity exponentially. Therefore, just 7 extra qubits of Sycamore means IBM needs to increase the size of Summit 33 times. A 17-qubit increase of Sycamore needs Summit to increase by thousands of times. This is the key difference between Summit and Sycamore. For each extra qubit, a conventional computer will have to scale its resources exponentially, and this is a losing game for the conventional computer.

We have to give Google the victory here, not because IBM is wrong, but because the principle of quantum supremacy, that a quantum computer can work as designed, solve a specific problem, and beat a conventional computer in computational time has been established. The actual demonstrationa more precise definition of reasonable time and its physical demonstrationis only of academic value. If 53 qubits can solve the problem, but with IBMs Summit still in the race, even if much slower, it is just a matter of time before it is well and truly beaten.

Of course, there are other ways that this particular test could fail. A new algorithm can be discovered that solves this problem faster, starting a fresh race. But the principle here is not a specific race but the way quantum computing will scale in solving a certain class of problems that classical or conventional computers cannot.

For problems that do not increase exponentially with size, the classical computers work better, are way cheaper, and do not require near absolute zero temperatures that quantum computers require. In other words, classical computers will coexist with quantum computers and not follow typewriters and calculators to the technology graveyards.

The key issue in creating viable quantum computers should not be confused with a race between classical computers and the new kid on the block. If we see the race as between two classes of computers only in terms of solving a specific problem, we are missing the big picture. It is simply that for classical computers, the solution time for a certain class of problems increases exponentially with the size of the problem, and beyond a certain size, we just cant solve them in any reasonable time. Quantum computers have the potential to solve such large problems requiring exponential computing power. This opens a way to solve these classes of problems other than the iffy route of finding new algorithms.

Are there such problems, and will they yield worthwhile technological applications? The Google problem, computing the future states of quantum circuits, was not chosen for any practical application. It was simply chosen to showcase quantum supremacy, defined as a quantum computer solving a problem that a classical computer cannot solve in a reasonable time.

Recently, a Chinese team led by Pan Jianwei has published a paper that shows another problema Boson sampling experiment with 20 photonscan also be a pathway to show quantum supremacy. Both these problems are constructed not to showcase real-world applications, but simply to show that quantum computing works and can potentially solve real-world problems.

What are the classes of problems that quantum computers can solve? The first are those for which the late Nobel laureate Richard Feynman had postulated quantum computers as a simulation of the quantum world. Why do we need such simulations, after all, we live in the macro-world in which quantum effects are not visible? Though such effects may not visible to us, they are indeed all around us and affect us in different ways.

A number of such phenomena arise out of the interaction of the quantum world with the macro-world. It is now clear that using classical computers we cannot simulate, for instance, protein folding, as it involves the quantum world intersecting with the macro-world. A quantum computer could simulate the probability of how many possible ways such proteins could fold and the likely shapes they could take. This would allow us to build not only new materials but also medicines known as biologics. Biologics are large molecules used for treating cancer and auto-immune diseases. They work due to not only their composition but also their shapes. If we could work out their shapes, we could identify new proteinsor new biological drug targets; or complex new chemicals for developing new materials. The other examples are solving real-life combinatorial problems such as searching large databases, cracking cryptographic problems, improved medical imaging, etc.

The business worldIBM, Google, Microsoftis gung-ho on the possible use of quantum computers for such applications, and that is why they are all investing in it big time. Nature reported that in 2017 and 2018, at least $450 million was invested by venture capital in quantum computing, more than four times more than the preceding two years. Nation-states, notably the United States and China, are also investing billions of dollars each year.

But what if quantum computers do not lead to commercial benefitsshould we then abandon them? What if they are useful only for simulating quantum mechanics and understanding that world better? Did we build the Hadron Colliderinvesting $13.25 billion, and with an annual running cost of $1 billiononly because we expected discoveries that will have commercial value? Or, should society invest in knowing the fundamental properties of space and time including that of the quantum world? Even if quantum computers only give us a window to the quantum world, the benefits would be knowledge.

What is the price of this knowledge?

This article was produced in partnership by Newsclick and Globetrotter, a project of the Independent Media Institute.

Read more here:

IBM vs. Google and the Race to Quantum Supremacy - Citizen Truth

Indian chemist has key chemical reactions named after him – BusinessLine

In modern Chemistry, names do matter, especially in pathbreaking chemical reactions or phenomenon.

Here is a sample of few chemical reactions -Grignard, Wittig & Barton, the Claisen condensation, Friedel-Crafts acylation, the Sharpless epoxidation, Grubbs olefin metathesis and Suzuki coupling.

These are all top scientists, discoverers or developers after whose names have been given to the reactions that they are identified with.. A few hundreds such reactions exist, especially in organic Chemistry.

DB Ramachary, a professor from the University of Hyderabad (UoH), has also joined this list with some outstanding research work in developing new and novel reactions.

The laboratory's contributions in terms of a slew of reactions are focused on using bio-friendly, amino acids as catalysts in developing novel approaches for drug development which is also sustainable as compared to chemical methods which use heavy metals like copper, Gold etc, which are both toxic and finite in resources, says Ramachary.

Some of these are the Ramachary Reductive Coupling, Ramachary-Bressy-Wang cycloaddition, Ramachary 2-Aminobuta 1,3 enyne catalysis, Ramachary Base Induced Ring Opening (BIRO) Reaction, Asymmetric Supramolecular-Organocatalysis: Ramachary, Organocatalytic AzideCarbonyl [3+2]-Cycloaddition etc. are also routinely used in the US, Japan, UK, China, Germany etc.

During the 20th century, as organic chemistry developed, chemists started associating useful reactions with the names of the discoverers or developers.

Many chemists from different nations contributed to this privileged list . In 1934, Indian chemist, K Venkataraman also contributed through his reaction and that was named after him along with Wilson Baker as BakerVenkataraman rearrangement.

During the past two decades, a few reactions developed in the Ramachary Lab at the School of Chemistry in UoH , have been recognised as highly useful for organic to medicinal to material chemists. Consequently, they have become well known organic reactions to be named after him.

These findings have received wide attention among researchers world-wide; it is expected that they will pave way to utilize for the design and synthesis of new drugs, materials and natural products in more economical manner, Ramachary told BusinessLine.

Read the rest here:
Indian chemist has key chemical reactions named after him - BusinessLine

Chemists taken aback as dinitrogen found to speed up some reactions – Chemistry World

Molecular nitrogen has been found to actually speed up some reactions that use ruthenium-based catalysts despite being considered inert for the purposes of most chemical reactions.1 This behaviour could also affect other catalytic processes, so dinitrogen should no longer be considered as a simple inert carrier gas, the team from the UK and China say.

Heterogeneous catalytic reactions usually consist of two or three phases, including a solid-phase catalyst, as well as gas- and/or liquid-phase reactants and solvents. Most studies focus on improving the catalysts, but as these processes occur at interfacial sites, species from the other two phases can also affect the catalytic properties. Dinitrogen is commonly used as carrier or protective gas in catalytic reactions because it is considered to be unreactive. But now chemists have discovered that the molecule can sometimes behave in unexpected ways.

Dermot OHare of the University of Oxford and colleagues investigated the hydrodeoxygenation of p-cresol to toluene over a titanium oxide supported ruthenium catalyst and found that introducing 6 bar dinitrogen caused a 4.3-fold activity increase at 160C under batch conditions. The greatest impact of this work is to demonstrate that a hitherto perceived unreactive molecule can now be observed to increase catalytic performance, OHare says. This is extremely surprising and unusual.

The researchers carried out experiments at different temperatures and using various ruthenium catalysts. Their results showed an enhancement on all the studied materials. DFT calculations helped them understand the mechanism involved. We think the nitrogen molecule may convert to a more reactive NNH species on the metal surface, OHare says. Jun Li at Tsinghua University, who also participated in the study, explains that this NNH pathway for dinitrogen activation, which he says mimics the biological pathway used by nitrogen-fixing bacteria, has been theoretically proposed for ammonia synthesis2 but had not been confirmed experimentally until now. This work provides the first experimental evidence of the unusual formation of NNH or NNHx species, he says.

Normally, nitrogen is considered extremely inert, which makes this proposal quite exciting, as such behaviour is unprecedented, says Michael Fryzuk of the University of British Columbia, Canada, who was not involved in the study. The role as a catalytic promoter facilitating protonation of surface-adsorbed hydroxyl species is quite enticing, but as the authors are careful to note, the role of nitrogen may also be to open up more sites on the ruthenium surface by removal of surface hydrogen atoms.

OHare thinks the new results could have a wider impact. This may be a more general concept and applicable for other metal-based catalyses, he says. Researchers should now add nitrogen to their gas streams to see what happens. Fryzuk agrees that this would be an interesting thing to do. There may be some surprises that await, he adds. Ji believes that the NNH pathway could become a useful strategy for ammonia production. On the theoretical side, we plan to explore a wide range of metals to determine which metal surface can facilitate this pathway the best. Then it might be used for nitrogen-to-ammonia conversion, he says.

Read the original:
Chemists taken aback as dinitrogen found to speed up some reactions - Chemistry World

Chemistry, trust lead Herd defensive line to success – Huntington Herald Dispatch

HUNTINGTON Anyone who has ever been a competitor knows there is no trust like that within yourself to get a job done.

The beauty of team sports is that, just like a player trusts in his or her own abilities, he or she also must build that same trust level within their teammates to see success.

For Marshalls 2019 football season, there is no better example of this than the Thundering Herd defensive line, led by defensive ends coach Cornell Brown and defensive tackles coach J.C. Price.

Marshall rotates as many as 11 or 12 players six defensive ends and five or six defensive linemen to apply constant pressure within a game. The result of that rotation is a Marshall defense that is tied for sixth in the Football Bowl Subdivision with 32 sacks and a team that is finishing games strong in the fourth quarter.

Marshall head coach Doc Holliday said that unselfish nature among those players is one way that he knows he has a special team.

Im sure all of these guys would like to play more, but they also like that feeling in the locker room after theyve won the game, Holliday said. Theyre an unselfish bunch and theyre playing well.

Channing Hames, a senior defensive tackle who has been in the program for five years now, said that building that trust level starts in the offseason when guys are working in the weight room and in individual drills. Hames can see those guys who are working hard beside him and going through every repetition at full speed, giving their all for the team, which helps create that bond between teammates.

One such player whom Hames has worked closely with is sophomore Jamare Edwards, who is Hames backup. Whereas at one time Hames would have wanted every rep, now he can see the benefit of shared time.

I think Jamare has done an outstanding job coming in and executing his job what hes supposed to do and even doing a little more just showing extra effort on plays and showing up when a play comes toward him, Hames said. I feel like when opportunities came, hes definitely (taken) advantage of that.

Things like that help me and the starters out to know that we can trust him to do what hes supposed to do when were not in there.

The defensive end rotation is even more impressive with Marquis Couch and Darius Hodge starting the games, but a six-man wave that includes names such as Koby Cumberlander, Sam Burton, Fermin Silva and Owen Porter, who all get action during a contest.

On average, Marshalls defense is only seeing around 66 plays per game with snaps being divided.

If Hodge played the number of snaps a lot of people in this league play, he may be leading our league in sacks, Holliday said. Gosh, he plays 30 plays a game. Then, you roll Koby Cumberlander and Sam Burton goes in there and plays welland you have Couch and Silva. We have about six defensive ends who are rolling in there to help us, and thats a good thing.

In the shorter picture of one week, Marshalls defensive linemen are at their best when the game is on the line.

I think we do a good job subbing in and out so by the time the fourth quarter comes, either me or one of us is ready to go in and cause havoc, Hames said.

In the longer scope of an entire season, that depth has been pivotal for the Herd in terms of injuries, which have been limited along the defensive line because players arent seeing the field as much. With the Herd in control of its destiny in Conference USAs East Division, it is now preparing for its final stretch run of the regular season a pivotal three-game race to the finish that starts with a Nov. 15 matchup against Louisiana Tech.

If things go as they have to this point in the season, Marshalls defensive line is going to be a key cog in seeing that success continue.

That entire unit is focused on quality not quantity as it moves toward its goals of a Conference USA championship.

Read more:
Chemistry, trust lead Herd defensive line to success - Huntington Herald Dispatch

UWMadison chemist searches for ways to bioengineer proteins within cells – University of Wisconsin-Madison

Andrew Buller, professor of chemistry at the University of WisconsinMadison, wants to add more building blocks to the bodys protein-making kit.

In nature, there exist 20 of these building blocks, called amino acids, which make up the proteins that perform the work required to sustain life. Buller says scientists can create more, allowing them to expand the ways in which cells build proteins.

Andrew Buller

You could think of this as having a Lego kit with just 20 different pieces, Buller says. What could you build if you had more? We build these new Lego bricks and then teach biological systems how to make them too.

Over the past two decades, scientists have been adding new amino acids to proteins, but it has required relying on organic chemists to first produce them in the lab. Buller is working to set up a system so that any molecular biologist can create the amino acids they want in a cell, using enzymes and an off-the-shelf chemical. This will make it easier and less expensive for biochemists to create the new molecules they want to use for research and medicine, he says.

People have wanted to do this for a long time, but there are a lot of barriers, Buller says. We are addressing one of the biggest, which is that its really expensive and it takes a lot of training in two different areas. If we can make it cheaper and so that you need one skill set instead of two, then everybody else is going to be able to use this technology.

This is the basis for Bullers recent $2.2 million 2019 National Institutes of Health Directors New Innovator Award, which is part of the agencys High-Risk, High-Reward program designed to support innovative research with the potential for substantial contributions to the field. By eliminating some of the pressure to find funding for these kinds of projects, they allow researchers time to work, discover and create.

Bullers group will repurpose how enzymes use vitamin B6, which is crucial for amino acid synthesis, to perform new types of reactions.

Now we get to focus on the science, Buller says, adding that the research could spawn methods of cheaper drug development. I think this is an important challenge for scientists to work on. We want to lower the barriers, both in terms of cost and difficulty, to make it easier to make new kinds of molecules.

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

See more here:
UWMadison chemist searches for ways to bioengineer proteins within cells - University of Wisconsin-Madison